ALKERMES PLC. (ALKS)
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Urban Edge Properties Invites You to Join Its Second Quarter 2026 Earnings Conference Call
TechnipFMC Announces Second-Quarter 2026 Earnings Release and Conference Call
Office Properties Income Trust Completes Chapter 11 Reorganization
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
First Horizon Corporation to Announce Second Quarter Financial Results on July 15, 2026
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
ICON Schedules First Quarter 2026 Earnings Conference Call
South Plains Financial, Inc. Announces Executive Leadership Transition
Global Ship Lease Announces Results of 2026 Annual Meeting of Shareholders